Glutathione metabolism in the prefrontal brain of adults with high-functioning autism spectrum disorder: an MRS study

Dominique Endres1†, Ludger Tebartz van Elst1†, Simon A. Meyer1, Bernd Feige1, Kathrin Nickel1, Anna Bubi2, Andreas Riedel1, Dieter Ebert1, Kathrin Nickel1, Anna Bubi2, Andreas Riedel1, Dieter Ebert1, Thomas Lange3, Volkmar Glauche5, Monica Biscaldi5, Alexandra Philipsen6, Simon J. Maier1† and Evgeniy Perlov1,7†

Abstract

Background: Autism spectrum disorder (ASD) is a neurodevelopmental disease characterized by difficulties in social communication, unusually restricted, repetitive behavior and interests, and specific abnormalities in language and perception. The precise etiology of ASD is still unknown and probably heterogeneous. In a subgroup of patients, toxic environmental exposure might lead to an imbalance between oxidative stress and anti-oxidant systems. Previous serum and postmortem studies measuring levels of glutathione (GSH), the main cellular free radical scavenger in the brain, have supported the hypothesis that this compound might play a role in the pathophysiology of autism.

Methods: Using the method of single-voxel proton magnetic resonance spectroscopy (MRS), we analyzed the GSH signal in the dorsal anterior cingulate cortex (dACC) and the dorsolateral prefrontal cortex (DLPFC) of 24 ASD patients with normal or above average IQs and 18 matched control subjects. We hypothesized that we would find decreased GSH concentrations in both regions.

Results: We did not find overall group differences in neurometabolites including GSH, neither in the dorsal ACC (Wilks’ lambda test; p = 0.429) nor in the DLPFC (p = 0.288). In the dACC, we found a trend for decreased GSH signals in ASD patients (p = 0.076).

Conclusions: We were unable to confirm our working hypothesis regarding decreased GSH concentrations in the ASD group. Further studies combining MRS, serum, and cerebrospinal fluid measurements of GSH metabolism including other regions of interest or even whole brain spectroscopy are needed.

Keywords: Autism spectrum disorder, Asperger syndrome, MR spectroscopy, Glutathione, Anterior cingulate cortex, DLPFC

Background

Autism spectrum disorder (ASD)

ASD is a neurodevelopmental disorder characterized by difficulties in social communication and unusually restricted, repetitive behavior and interests with a strong desire for routines [1, 2]. In addition, there are specific abnormalities in language, sensory, and social perception [2]. ASD is an etiologically and phenotypically heterogeneous disorder [3].
psychiatric disorders such as depression, anxiety, attention deficit hyperactivity disorder (ADHD), psychotic symptoms, or emotionally unstable syndromes [7, 8]. The increasing importance of ASD is caused by the high prevalence rates, the fact that ASD is a life-long condition, and the high rates of psychiatric comorbidity [2].

GSH and etiology of ASD
The precise etiology of ASD is still unknown and probably heterogeneous [1, 2, 9, 10]. Genetic aspects play a certain role in ASD [2, 11]. Moreover, ASD may develop as a consequence of acquired central nervous system diseases, such as traumatic brain injury with epilepsy or encephalitis [2, 4]. We earlier suggested an excitatory/inhibitory imbalance. Following this hypothesis, a disturbed equilibrium between the most important excitatory neurotransmitter glutamate and the most important inhibitory transmitter γ-amino-butyric acid (GABA) might destabilize cortical networks, which in turn are related to autistic symptoms [9,10]. Another pathophysiological hypothesis of autism holds that an imbalance between oxidative stress and antioxidant systems (in particular glutathione [GSH], the main cellular free radical scavenger in the brain), triggered by toxic environmental exposures, might play a central role in autism. The so-called redox/methylation hypothesis is able to quantify additional findings in ASD together (“A ‘unified field theory’ of autism”) [12]. An imbalance between oxidative stress and antioxidant systems might be triggered by toxic environmental exposures such as to heavy metals and xenobiotics. It is assumed that such an imbalance might lead to neuronal damage in genetically predisposed individuals [13–15]. Similar pathophysiological models have been discussed for schizophrenia [16]. Such theories for ASD have been supported by laboratory and postmortem findings of altered GSH concentrations in ASD patients. GSH is the brain’s dominant antioxidant, showing decreased blood levels of reduced GSH and increased concentrations of oxidized glutathione (GSSG) in the ASD group compared to controls on a meta-analytical level [14]. Postmortem studies found a disturbed redox ratio as a marker of oxidative stress in the cerebellum and temporal cortex [3, 17].

The antioxidant glutathione (GSH)
GSH is the main cellular free radical scavenger in the brain, playing a key role in protecting cells from exogenous and endogenous toxins, particularly in the brain [3, 14]. It is a tripeptide consisting of glutamate, cysteine, and glycine (L-c-glutamyl-L-cysteinylglycine). Cysteine is the rate-limiting amino acid for the synthesis of GSH [14]. It changes between the reduced monomeric (GSH) and oxidized dimeric forms (GSSG) in the scavenging process [16, 18]. The GSH/GSSG relation is an indicator of cellular redox status [19]. In the healthy brains, the ratio of GSH/GSSG is over 100 [20, 21] and GSSG is normally below MRS detection levels. GSH is essential for the synthesis and degradation of proteins and the formation of the deoxyribonucleotide precursors of DNA. It protects the cell against reactive oxygen compounds and conjugates with foreign compounds. It is also a cofactor in several other reactions [21].

Magnetic resonance spectroscopy (MRS) as a tool for assessing GSH levels in vivo
MRS is a unique, non-invasive, and non-radioactive method of measuring different neurometabolites. For ASD research, MRS is of great interest because it is the only method for the non-invasive measurement of the main antioxidant, GSH, and of the major excitatory (glutamate, Glu) and inhibitory (γ-aminobutyric acid, GABA) transmitters in the human brain. In this study, we used the single-voxel proton MRS technique, which enables metabolite quantification in a predetermined volume of interest (VOI) with internal water reference scaling. Moreover, MRS is able to quantify additional neurometabolites, including creatine (Cre), which is a marker of the brain’s energy metabolism; choline (Cho) compounds or total-choline (t-Chol), which are markers of membrane/phospholipid turnover and white/gray matter differences; N-acetylaspartate (NAA), a marker of neuronal and axonal integrity; and myo-inositol (mI), an organic osmolyte and second messenger [21, 22].

Methodological MRS aspects
For the detection and quantification of GSH, various more or less sophisticated MRS methods have been applied. As apart from GSH, other important brain metabolites were to be detected and quantified in our study; we used short-TE PRESS (echo time-point-resolved spectroscopy) for good overall signal-to-noise ratio (SNR) and acceptable scan durations. Short-TE PRESS has been validated for GSH quantification with phantom experiments by others [23] and has been applied in clinical studies for voxel locations, which are similar to ours [24] or closer to the sinuses and thus more challenging in terms of spectral quality [23]. MEGA-PRESS (Meshcher Garwood-PRESS), which has been established as a gold standard for GABA detection, has also been proposed for GSH editing. However, a good editing efficiency requires long echo times (TE = 120 ms [25]), for which the rather short T2 of GSH (T2 = 67 ms at 4T [26]) gives rise to considerable signal loss compared to short-TE PRESS. 2D MRS methods such as JPRESS (J-resolved pointe-resolved spectroscopy) or COSY (correlation spectroscopy) have also been proposed for GSH detection. However, the 2D-fitting methods required for quantification of these spectra still
lack the robustness of the established linear combination of a model spectra (LCModel) algorithm.

**Previous MRS findings in the prefrontal cortex**

Only one study analyzing GSH concentrations in ASD has been published to date. Durieux et al. [24] found no GSH signal differences between male ASD patients and age- and IQ-matched controls in the basal ganglia and the dorsomedial prefrontal cortex (DMPFC). Several schizophrenia studies have been performed with mixed results: In the largest study in first-episode schizophrenic patients, 22% higher medial temporal lobe GSH concentrations were found compared to the control group [27]. However, two other studies analyzing prefrontal regions showed no group differences between the schizophrenia and healthy control groups [28, 29]. Studies analyzing the established neurometabolites in ASD have mainly focused on the anterior cingulate cortex (ACC). Most of these studies found abnormal glutamate concentrations [9, 10, 30–32]. Cochran et al. [33] found higher glutamine (Gln) levels and lower GABA/Cre levels in ASD, supporting the idea of an excitatory (Glu)/inhibitory (GABA) imbalance hypothesis. Anterior cingulate NAA, t-Cho, Cre, and ml signals were also found to be altered in some earlier studies [9, 10, 31, 34–37]. In the left dorsolateral prefrontal cortex (DLPFC), low NAA/Cre levels were found in the study by Fujii and colleagues [36], but no significant differences were found in two other studies [34, 38].

**Rationale of our study**

The main aim of this study was to compare GSH signals in high-functioning ASD patients with normal and above average intelligence quotients (IQ >90) and those in healthy controls. We excluded patients with subnormal IQs because of their possible link to syndromal and secondary forms of autism. We decided to analyze the dorsal ACC because of the recently reported neurochemical abnormalities in this region [9, 10]. In addition, we analyzed the DLPFC, which is an important part of the dorsolateral prefrontal circuits [39]. Alterations in these circuits lead to executive dysfunction [39]. The DLPFC is also associated with deficits in theory of mind [38, 40]. Neurochemical alterations in the DLPFC were described earlier [9]. Based on the evidence from several laboratory and postmortem studies [3, 14, 17], we hypothesized that we would find decreased GSH concentrations in the dACC and DLPFC of ASD patients. Moreover, the study examined Cre, t-Cho, Glx = Glu + Gln, NAA, and ml signals. On the basis of earlier studies suggesting an excitatory-inhibitory imbalance mechanism [9, 10], we hypothesized that we would find altered Glx levels in the ACC.

**Methods**

All patients were recruited at the Freiburg Center for the Diagnosis and Treatment of Autism (University Center for Autism Spectrum, Universitäres Zentrum Autismus Spektrum Freiburg, UZAS; www.uniklinik-freiburg.de/psych/live/patientenversorgung/schwerpunkte/schwerpunkt-asperger.html).

**Patient assessment**

The diagnostic process followed the National Institute for Health and Clinical Excellence (NICE) guidelines for adult autism (http://guidance.nice.org.uk/CG142/NICE-Guidance/pdf/English). Only patients fulfilling the ICD-10 F84.5 and DSM-IV 299.00 criteria were included. The structured diagnostic procedure was performed by a multiprofessional diagnostic team with three experienced senior consultant psychiatrists and two fully qualified senior psychologists. Anamnesis was conducted over several sessions and included questioning of caregivers or relatives (parents, siblings, partners, etc.) and behavioral observations. The diagnosis was made by all persons involved in the diagnostic process, incorporating at least two experienced consultant psychiatrists or psychologists. Psychometric assessments using the autism-spectrum quotient (AQ) [41], empathy quotient (EQ) [42], Australian Scale of Asperger’s Syndrome [43], Social Responsiveness Scale [44], Bermond-Vorst Alexithymia Questionnaire [45], and Adult Asperger Assessment [46] were included in the diagnostic process. The Wender Utah Rating Scale (WURS-k) [47] for ADHD symptoms and the Beck Depression Inventory score (BDI) [48] for depressiveness were collected to assess the most frequent comorbidity and to control for influences of their symptoms on metabolic signals. General crystalline intelligence was assessed using the multiple-choice word test B (MWT-B) [49]. In unclear cases, the Autism Diagnostic Interview-Revised [50], the autism diagnostic observation schedule-generic [51], and/or behavioral assessments as an in-patient were additionally included. To avoid a heterogeneous study sample, we excluded secondary and obviously syndromal forms of ASD and only included patients with normal or above average IQ.

**Healthy control group**

The control group was comprised of age-, IQ-, and gender-matched healthy subjects. Controls with relevant medical, psychiatric, or neurological diseases were excluded from the study. All controls were assessed with the AQ, EQ, WURS-k, BDI, and MWT-B questionnaires. AQ scores > 30, EQ scores ≤ 30, WURS-k scores > 30, BDI scores > 18, and IQ scores < 90 led to exclusion from the study.

Endres et al. Molecular Autism (2017) 8:10
MRS procedure

All measurements were performed at the University of Freiburg on a 3 Tesla Siemens Magnetom TIM Trio system (Erlangen, Germany). For signal reception, a 32-channel head coil was used. First, a standard magnetization-prepared rapid gradient echo (MPRAGE) T1-weighted anatomical scan was recorded with the following parameters: field of view (FOV) = 256 × 256 mm³, repetition time (TR) = 2200 ms, TE = 4.11 ms, flip angle = 12°, and voxel size = 1 × 1 × 1 mm³. Spectroscopic measurements were performed in the dorsal anterior cingulate cortex (30 × 20 × 25 mm; 15.0 mL) and in the left dorsolateral prefrontal cortex (25 × 25 × 25 mm; 15.6 mL) using a PRESS sequence with a TR of 1500 ms, a TE of 30 ms, and a number of slices of 256. The PRESS sequence used in this work contained Hamming-filtered sinc pulses with a bandwidth of 3365 Hz for excitation and Mao pulses with a bandwidth of 1153 Hz for refocusing. The signal readout consisted of 1024 sampling points covering a bandwidth of 1200 Hz. For metabolite quantification with the internal water reference method, a water spectrum was acquired using the same protocol as for the acquisition of the actual spectra, but the radio frequency pulses for water suppression were switched off, and the number of spectral averages was reduced to 16 [52]. For spectral fitting and quantification, the well-established and validated LCModel algorithm was applied (http://s-provencher.com/lcmodel.shtml). The metabolite basis set for LCModel quantification was simulated numerically with Matlab, using chemical shifts and coupling constants derived from the literature, and fully shaped RF waveforms of the slice-selective refocusing pulses as employed by the scanner [53]. For spectroscopic analyses, only spectra with Cramér-Rao lower bounds (CRLBs) smaller than 20% for the main metabolites were included [54, 55]. Finally, the 3D MPRAGE datasets were segmented into gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF), using a unified segmentation approach [56] implemented in Statistical Parametric Mapping, Version 8 (SPM8; www.fil.ion.ucl.ac.uk/spm/software/spm8). For each VOI, the partial volumes of GM, WM, and CSF were computed from this segmentation. These partial volumes were used for estimation of the water content in the VOI, which was needed for quantification and for metabolite concentration correction, assuming that the measured brain metabolites are only contained in GM and WM, but not in CSF [9, 10, 56, 57] (Figs. 1 and 2).

Study sample

Table 1 gives an overview of the study sample. In the ASD group, only one patient had to be excluded due to technical reasons; in the control sample, we excluded five subjects because of suprathreshold psychometric findings and one control due to technical reasons.

Statistical analyses

Spectroscopic, demographic, and psychometric data were transferred to a Statistical Package for the Social Sciences (SPSS inc., Stanford USA) database. For group comparisons of continuous variables (age, nicotine consumption, psychometric scores), we performed two-sided independent sample t tests. For group comparisons of gender, we calculated Pearson’s two-sided chi squared test. The neurometabolite concentrations in the dACC and DLPFC of the ASD and control groups were compared using a multivariate analysis of covariance (MANCOVA) and employing a general linear model. The factor group was chosen as the fixed factor and the neurometabolites (GSH, Cre, t-Cho, Glx, NAA, and mI) as dependent variables. No covariates were included in the first MANCOVA. The possible confounding factors of age [58], IQ [59], gender [60, 61], and nicotine consumption [62, 63] did not differ between the groups. Therefore, we did not include these variables as covariates in the main analyses (as we did in earlier studies [57]). However, we performed another analysis with age, IQ, and nicotine consumption as covariates to exclude effects due to within-subject variations in these parameters. To test for an overall group effect across all six neurometabolites, a multivariate Wilks’ lambda test was
used in both cases. When comparing medicated and unmedicated ASD patients, we found significant differences in the gender ratio; therefore, we also included gender (besides group [medicated vs. unmedicated]) as a fixed variable in the respective MANCOVA. Correlation analyses were performed using the Pearson correlation coefficient. To test for the influence of age on the correlation between GSH and IQ, we performed a partial correlation, adjusted for age. For overall and single-group differences in neurometabolite signals, the level of significance was corrected for multiple tests using the Bonferroni approach (\( p < 0.025 \) due to performing the measurements in two independent regions). The same significance level of \( p < 0.025 \) was used for the correlation analyses (because of the two measured regions), and for all other calculations, a \( p \) value <0.05 served as the criterion of significance.

**Results**

**Demographic and psychometric data**
The ASD and control groups did not differ significantly in age, IQ, nicotine consumption, and gender. The age range varied from 25 to 57 years in the ASD group and from 24 to 60 years in the control sample. Table 2 also gives detailed information about levels of psychometric scores, as well as education and occupational situation for all participants.

**MRS results**
We acquired robust data with high SNR (40.452 ± 27.974 for the ACC VOI and 39.0 ± 21.462 for the DLPFC voxel) and low average CRLBs for GSH (6.4% for the ACC voxel and 7.0% for the DLPFC voxel). Using a multivariate analysis of covariance, significant group differences were found neither in the dACC (Wilks’ lambda test without covariates \( p = 0.429 \), with covariates \( p = 0.564 \)) nor in the DLPFC (without covariates \( p = 0.288 \), with covariates \( p = 0.262 \); Table 3).

**GSH**
The correlation analysis for the ASD sample (\( N = 24 \)) in the dACC VOI revealed a significant negative correlation between the GSH signal and IQ (\( r = -0.549; p = 0.005, N = 24 \)) and age (\( r = -0.567, p = 0.004, N = 24 \)).

**Other neurometabolites**
The anterior cingulate mI signals were also lower in the ASD group (1.79 mM ± 0.37; control group, 1.98 mM ± 0.26; \( p = 0.076 \)) and higher in the DLPFC VOI (6.91 ± 0.34 to 6.63 ± 0.35; \( p = 0.013 \)).

**Analysis of dimensional associations**

**GSH**
The correlation analysis for the ASD sample (\( N = 24 \)) in the dACC VOI revealed a significant negative correlation between the GSH signal and IQ (\( r = -0.549; p = 0.005, N = 24 \)) and age (\( r = -0.567, p = 0.004, N = 24 \)).

Table 1 Autism spectrum disorder and healthy control samples with reasons for exclusion

|                      | Autism spectrum disorder | Controls |
|----------------------|--------------------------|----------|
| Included subjects    | 25                       | 24       |
| Technical reasons for further exclusion | 1 × bad spectral quality  | 1 × bad spectral quality |
| Post hoc information about psychometric exclusion criteria | 0 | 1 × BDI-score >18, 1 × WURS-k-score >30, 2 × EQ-score ≤30, 1 × IQ <90 |
| Number of spectra for statistical analysis | 24 | 18 |

BDI Beck Depression Inventory score, WURS-k Wender Utah Rating Scale, EQ empathy quotient, IQ intelligence quotient
however, a partial correlation for GSH and IQ—corrected for age—was not significant ($r = -0.290; df = 21; p = 0.179, N = 24$).

**Other neurometabolites**
In addition, we found a highly significant negative correlation between age and the Glx signal in the DLFC ($r = -0.730, p < 0.001, N = 24$) (Table 4).

**Medication effects**
Finally, we compared medicated ($n = 13$) and unmedicated ASD patients ($n = 11$). Both groups showed no significant differences in the possibly confounding factors of age, IQ, and nicotine consumption. Since they differed in gender ratio, we performed a MANCOVA with the fixed variables of medication and gender. For both VOIs, we found no significant group differences (Wilks’ lambda test, $p = 0.891$ for the dACC and $p = 0.484$ for the DLPFC).

**Discussion**
The main finding of this study is the absence of significant group differences in the dACC or in the DLPFC with respect to GSH. Therefore, we were not able to confirm our working hypothesis regarding decreased GSH concentrations in the ASD group.

**Limitations**
First, potential limitations should be considered. The diagnostic procedure was performed by an experienced, multiprofessional diagnostic team following the NICE guidelines for adult autism. To avoid a heterogeneous study sample, we included only patients with normal or above average IQs. Therefore, our cohort is not representative for low-functioning autism. The advanced age of our patients should also be considered. Because ASD is a neurodevelopmental disorder, the GSH metabolism could have normalized over the years. The sample size is comparable with other studies analyzing GSH metabolism [24, 27]. One limitation is that we analyzed patients with and without medication. Therefore, our results

### Table 2: Demographic and psychometric information for the autism spectrum disorder and control groups

|                      | ASD ($n = 24$) | Controls ($n = 18$) | Statistics |
|----------------------|----------------|--------------------|------------|
| Age                  | 40.54 ± 10.279 | 37.17 ± 10.983     | $p = 0.313$|
| Intelligence quotient| 114.29 ± 15.213| 113.00 ± 13.920    | $p = 0.779$|
| Gender               | 12 m:12 f      | 8 m:10 f           | $p = 0.721$|
| Nicotine             | 2.292 ± 5.894  | 2.222 ± 6.691      | $p = 0.972$|
| Autism-spectrum quotient| 39.08 ± 6.386  | 12.94 ± 5.504      | $p < 0.001$|
| Empathy quotient     | 17.38 ± 9.523  | 47.94 ± 9.710      | $p < 0.001$|
| Wender Utah Rating Scale | 33.75 ± 16.690 | 8.72 ± 7.954       | $p < 0.001$|
| Beck Depression Inventory score | 17.25 ± 12.365 | 3.22 ± 4.236       | $p < 0.001$|
| Level of education   |                |                    |            |
|                      | Low school degree, 1 (4.2%) | Low school degree, 0 (0%) |          |
|                      | Medium school degree, 3 (12.5%) | Medium school degree, 3 (16.7%) |          |
|                      | High school degree, 9 (37.5%) | High school degree, 6 (33.3%) |          |
|                      | University degree, 9 (37.5%) | University degree, 9 (50%) |          |
|                      | Other, 2 (8.3%) | Other, 0 (0%)      |            |
| Occupational situation |                |                    |            |
|                      | Full-time employed, 13 (54.2%) | Full-time employed, 7 (38.9%) |          |
|                      | Part-time employment, 4 (16.7%) | Part-time employment, 4 (22.2%) |          |
|                      | In vocational training/studying, 1 (4.2%) | In vocational training/studying, 7 (38.9%) |          |
|                      | Pension, 1 (4.2%) | Pension, 0 (0%)     |            |
|                      | Unemployed, 4 (16.7%) | Unemployed, 0 (0%) |            |
|                      | Other, 1 (4.2%) | Other, 0 (0%)       |            |
| Psychiatric medication (in the last 3 months) | No, 11 | No, 18 |          |
|                      | AD, 6 | AD, 0 |            |
|                      | NL, 1 | NL, 0 |            |
|                      | AD + NL, 5 | AD + NL, 0 |            |
|                      | AD + MPH, 1 | AD + MPH, 0 |            |

ASD autism spectrum disorder, IQ intelligence quotient, AD antidepressants, NL neuroleptics, MPH methylphenidate
For references, see text
might be influenced by medication-induced oxidative stress [64], and further studies should analyze unmedicated patients. However, in our sample, we did not find any significant differences in neurometabolite concentrations between medicated and non-medicated patients. We therefore do not assume a relevant medication effect in our cohort.

For MRS measurements, we used the well-established single-voxel 1H-MRS method (applying short-TE PRESS). The accuracy of GSH detection with such standard MRS methods is a strongly disputed topic in the MRS community (see “Background” section). However, standard MRS sequences (PRESS and STEAM) have previously been applied in a number of other GSH studies in humans, and to date, there is no clear evidence of better in vivo GSH quantification accuracy with different editing methods such as MEGA-PRESS [23, 27, 65–67]. The measurement of GSH levels is complicated due to significant resonance overlap with other metabolites [21]. By using a 32-channel head coil at a field strength of 3 T and the manual shimming procedure, we obtained robust data with high SNR and low average CRLBs for GSH. We were only able to measure GSH signals. The GSH/GSSG ratio would have been a better indicator of cellular redox status; however, the GSSG concentration was below the MRS detection limit [68]. We used the established and stable SVS method, which allows only the measurement of preselected VOIs. Therefore, we were only able to measure the concentrations of neurometabolites of interest in preselected VOIs (dACC and DLPFC). Data exclusion was performed based on the CRLBs determined by LCModel (rejection for CRLBs >20% for the main metabolites). In psychiatric MRS studies, metabolite concentrations are often reported as ratios to the Cre concentration, which is considered to be relatively unaffected by most pathological conditions. In our study, we performed metabolite quantification with internal water reference scaling to avoid bias arising from varying levels of Cre. In fact, we did find a trend of decreased Cre signals in the dACC and a tendency for Cre signals to be increased in the DLPFC of patients, suggesting that metabolite quantification is more robust than calculating ratios over Cre, as in other ASD studies. The LCModel software allowed all spectra to be treated the same.

**Interpretation of our findings in the context of earlier studies**

This was the first study analyzing anterior cingulate GSH signals, and we only found a tendency for decreased GSH concentrations. The only currently available study analyzing GSH concentrations in ASD found no differences in the left basal ganglia and the left DMPFC [24]. Therefore, our observation of normal GSH concentrations in the DLPFC of patients, suggesting that metabolite quantification is more robust than calculating ratios over Cre, as in other ASD studies. The LCModel software allowed all spectra to be treated the same.

---

**Table 3** Neurometabolic results for both analyzed regions (in mM)

|                  | Dorsal anterior cingulate cortex | MANCOVA without covariates (Wilks’ lambda test $p = 0.429$) | MANCOVA with covariates* (Wilks’ lambda test $p = 0.564$) | Dorsolateral prefrontal cortex | MANCOVA without covariates (Wilks’ lambda test $p = 0.288$) | MANCOVA with covariates* (Wilks’ lambda test $p = 0.262$) |
|------------------|---------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                  | ASD ($n = 24$)                  | Controls ($n = 18$)                                       |                                                           | ASD ($n = 24$)              | Controls ($n = 18$)                                       |                                                           |
| GSH              | 1.7939                          | 1.9810                                                   | $p = 0.076$                                               | 1.6017                      | 1.6247                                                   | $p = 0.076$                                               | 1.6017                      | 1.6247                                                   | $p = 0.076$                                               |
|                  | 0.37068                         | 0.26364                                                  |                                                          | 0.18921                     | 0.19985                                                   |                                                          | 0.18921                     | 0.19985                                                   |                                                          |
| Cre              | 7.4948                          | 7.9657                                                   | $p = 0.048$                                               | 6.9109                      | 6.6330                                                   | $p = 0.013$                                               | 6.9109                      | 6.6330                                                   | $p = 0.013$                                               |
|                  | 0.91646                         | 0.39453                                                  |                                                          | 0.33509                     | 0.35355                                                   |                                                          | 0.33509                     | 0.35355                                                   |                                                          |
| t-Cho            | 1.8900                          | 1.9926                                                   | $p = 0.213$                                               | 1.8507                      | 1.8289                                                   | $p = 0.757$                                               | 1.8507                      | 1.8289                                                   | $p = 0.757$                                               |
|                  | 0.27320                         | 0.24132                                                  |                                                          | 0.18029                     | 0.27268                                                   |                                                          | 0.18029                     | 0.27268                                                   |                                                          |
| Glx              | 11.7396                         | 12.5834                                                  | $p = 0.142$                                               | 9.4585                      | 9.2360                                                   | $p = 0.396$                                               | 9.4585                      | 9.2360                                                   | $p = 0.396$                                               |
|                  | 2.14178                         | 1.21151                                                  |                                                          | 0.97482                     | 0.58407                                                   |                                                          | 0.97482                     | 0.58407                                                   |                                                          |
| NAA              | 8.1840                          | 8.8939                                                   | $p = 0.168$                                               | 8.8931                      | 8.7972                                                   | $p = 0.661$                                               | 8.8931                      | 8.7972                                                   | $p = 0.661$                                               |
|                  | 1.82291                         | 1.29632                                                  |                                                          | 0.75962                     | 0.59745                                                   |                                                          | 0.75962                     | 0.59745                                                   |                                                          |
| ml               | 5.8211                          | 6.3095                                                   | $p = 0.018$                                               | 5.0549                      | 4.9064                                                   | $p = 0.344$                                               | 5.0549                      | 4.9064                                                   | $p = 0.344$                                               |
|                  | 0.73532                         | 0.46517                                                  |                                                          | 0.50464                     | 0.48836                                                   |                                                          | 0.50464                     | 0.48836                                                   |                                                          |

ASD, autism spectrum disorder; MANCOVA, multivariate analysis of covariance; $p$ value to test for differences between groups; GSH, glutathione; Cre, creatine; t-Cho, phosphorylcholine + glycerylphosphorylcholine; Glx, glutamate + glutamine; NAA, N-acetylaspartate; ml, myo-inositol

*Age, intelligence quotient, and nicotine consumption
increased Glx levels were found in the ACC [31, 32], suggesting fluctuating levels of glutamate. Similar patterns of findings are reported in other neuropsychiatric conditions like epilepsy or anti-N-methyl-D-aspartate-receptor encephalitis [9, 69]. GSH and Glx metabolisms are closely related: GSH is synthesized from Glu, cysteine, and glycine [21]. Glutathione is a physiologic reservoir of neuronal Glu [70]. Glutamatergic metabolism seems to play an important role in ASD, possibly related to a cybernetic imbalance between neuronal excitation and inhibition [9, 10]. Glu is the major excitatory neurotransmitter [71], and Gln is its precursor and storage form in astrocytes [53]. Low-plasma Gln may deplete GSH, because Gln provides Glu to synthesize glutathione; GSH depletion may deplete Glu for the same reason [12]. In their ASD meta-analysis, Frustraci et al. found decreased blood levels of reduced glutathione (27%) and increased concentrations of oxidized glutathione (GSSG; 45%) relative to controls [14], suggesting a role of redox imbalance in the pathogenesis of ASD. Postmortem studies examining the temporal cortex and the cerebellum showed decreased GSH/GSSG ratios as a marker for oxidative stress [3, 17]. In the current study, we were not able to detect significant group differences in GSH signals between patient and control groups in the dACC and the DLPFC. Our results might be influenced by several factors such as medication (see “Limitations” section). Therefore, the examination of further regions, especially the temporal cortex and the cerebellum (because of the earlier described alterations in postmortem studies) in medication-free ASD patients should be performed. In addition, we found a trend for reduced ml concentrations in the dACC. Reduced ml levels may be associated with abnormal developmental processes via abnormal astrocyte density or altered neuronal growth [72], as shown in children with ASD [72, 73]. However, earlier findings are inconsistent [35, 72]. The trend for alterations in the Cre signals might be associated with brain-region-specific altered energy metabolism [22]. Decreased Cre signals, as observed in the dACC, are in line with the research of Bejjani et al. [31]. A tendency for higher Cre concentrations in the ASD group has not been described previously.

The dimensional analyses showed dACC GSH signal to be linked to IQ and age but not to autistic symptoms. We found a negative correlation between the GSH signals in the dACC and the IQ scores; the association between high IQ figures and low GSH levels is contrary to earlier research, which assumed impairment in cognitive function with reducing GSH levels [74]. Moreover, dACC GSH signals in the ASD collective correlated negatively with age; earlier studies also described an age-dependent decline of GSH concentrations [21]. A partial correlation between GSH and IQ, corrected for age, was not significant.

**Conclusions**

We were not able to detect significant alteration in GSH levels in the dACC and DLPFC of ASD patients. Significantly decreased GSH levels were earlier reported in blood and postmortem studies of the temporal cortex and the cerebellum [17]. Further MRS studies should focus on the temporal cortex and the cerebellum in medication-free ASD patients. Moreover, we suggest a combined blood and MRS measurement of GSH signals. Whereas the MRS measurements allow regional metabolic investigations in certain brain regions, blood analyses would allow the determination of the whole redox system by also measuring GSSG signals.

### Table 4 Correlation analyses for the autism spectrum disorder group (a p value of <0.025 served as the criterion of significance)

| Group                        | AQ    | EQ    | WURS-k | BDI   | IQ    | Age   |
|------------------------------|-------|-------|--------|-------|-------|-------|
| **Anterior cingulate cortex**|       |       |        |       |       |       |
| GSH                          | 0.077 | −0.193| 0.287  | −0.006| −0.549| −0.567|
| Cre                          | 0.721 | 0.366 | 0.174  | 0.978 | 0.005 | 0.004 |
| GSH                          | 0.183 | −0.373| −0.103 | −0.082| −0.329| −0.310|
| t-Cho                        | 0.393 | 0.072 | 0.632  | 0.702 | 0.117 | 0.140 |
| t-Cho                        | 0.296 | −0.268| 0.063  | 0.010 | −0.106| −0.195|
| Glx                          | 0.175 | 0.206 | 0.770  | 0.964 | 0.622 | 0.360 |
| NAA                          | 0.301 | −0.394| 0.104  | −0.019| −0.370| −0.346|
| NAA                          | 0.152 | 0.057 | 0.628  | 0.931 | 0.075 | 0.098 |
| ml                           | 0.081 | 0.053 | 0.974  | 0.634 | 0.159 | 0.140 |
| ml                           | −0.011| −0.040| −0.013 | −0.057| −0.289| −0.339|
| ml                           | 0.959 | 0.853 | 0.952  | 0.793 | 0.171 | 0.105 |
| **Dorsolateral prefrontal cortex** |       |       |        |       |       |       |
| GSH                          | −0.014| −0.058| 0.126  | 0.154 | −0.020| −0.166|
| Glx                          | 0.950 | 0.790 | 0.556  | 0.471 | 0.927 | 0.438 |
| Cre                          | 0.042 | −0.176| −0.287 | −0.283| −0.136| −0.115|
| t-Cho                        | 0.847 | 0.410 | 0.173  | 0.180 | 0.527 | 0.593 |
| t-Cho                        | −0.226| 0.443 | −0.010 | −0.027| 0.434 | 0.097 |
| Glx                          | 0.289 | 0.030 | 0.964  | 0.901 | 0.034 | 0.653 |
| Glx                          | 0.079 | 0.162 | 0.312  | −0.179| −0.454| −0.730|
| NAA                          | 0.713 | 0.450 | 0.138  | 0.402 | 0.026 | 0.000 |
| NAA                          | −0.038| −0.297| 0.183  | 0.033 | −0.341| −0.391|
| ml                           | 0.861 | 0.159 | 0.391  | 0.880 | 0.103 | 0.059 |
| ml                           | −0.205| 0.310 | 0.004  | −0.349| 0.005 | 0.035 |
| ml                           | 0.336 | 0.141 | 0.987  | 0.994 | 0.982 | 0.870 |

Presented are the Pearson correlation coefficients (above) and p values (below)

AQ: autism quotient, EQ: empathy quotient, WURS: Wender Utah Rating Scale, BDI: Beck Depression Inventory score, GSH: glutathione, Cre: creatine, t-Chol: phosphocholine + glycerylphosphocholine, Glx: glutamate + glutamine, NAA: N-acetylaspartate, ml: myo-inositol (for references, see text)
Moreover, CSF measurements of the GSH/GSSG ratios could provide additional information [75]. The topic of antioxidants is of high public interest and important for patients because of the possible treatment options with supplemental antioxidants (e.g., with N-acetylcysteine, a GSH precursor) [18].

Abbreviations
ADHD: Attention deficit hyperactivity disorder; AQ: Autism-spectrum quotient; ASD: Autism spectrum disorder; BDI: Beck Depression Inventory score; Cerc: Creatine; CRLBs: Cramér–Rao lower bounds; CSF: Cerebrospinal fluid; dACC: Dorsal anterior cingulated; DLPC: Dorsolateral prefrontal cortex; DMPFC: Dorsomedial prefrontal cortex; EQ: Emotion quotient; FOX: Field of view; GABA: γ-Aminobutyric acid; Gln: Glutamine; Glu: Glutamate; GM: Gray matter; GSH: Glutathione; GSSG: Glutathione disulfide; IQ: Intelligence quotient; LCMODEL: Linear combination of model spectra; MANCOVA: Multivariate analysis of variance; mI: myo-Inositol; MPRAGE: Magnetization-prepared rapid gradient echo; MRS: Magnetic resonance spectroscopy; MWT-B: Multiple-choice word test B; NAA: N-Acetylaspartate; NICE: National Institute for Health and Clinical Excellence; PRESS: Point-resolved spectroscopy; SPM: Statistical Parametric Mapping; SVS: Single-voxel spectroscopy; T: Tesla; t-Cho: Total-choline; TE: Echo time; TR: Repetition time; VOI: Volume of interest; WM: White matter; WURS: Wender Utah Rating Scale

Acknowledgements
Not applicable.

Funding
The study was financed by the Department for Psychiatry and Psychotherapy, University Medical Center Freiburg. There was no other funding.

Availability of data and materials
Not applicable.

Authors’ contributions
EP initiated the study. DEn and LTvE wrote the paper. BF, TL, and VG gave the technical support. DEn, LTvE, SAM, BF, KN, AB, AR, DEb, TL, VG, MB, AP, SJM, and EP were crucially involved in the theoretical discussion and performing of the manuscript. All authors read and approved the final version of the manuscript.

Competing interests
LTvE has received advisory boards, lectures, or travel grants within the last 3 years: Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen, and Cyberonics. AP has received advisory board fees from Lilly, advisory board and lecture fees from Medice, Novartis, and Shire, congress support from Servier, and a travel grant from Lundbeck. She has also authored books and articles on adult ADHD published by Elsevier, Hogrefe, Schattauer, MWW, Kohlhammer, and Karger. DEn, SAM, BF, KN, AB, AR, DEb, TL, VG, MB, SJM, and EP declare that they have no competing interests.

Consent for publication
Not applicable.

Ethical approval and consent to participate
The study received the approval from the local ethics committee (Faculty of Medicine, Freiburg University, EK-Fr 252/12). All patients and controls gave written informed consent to the participation in the imaging project.

Author details
1Section for Experimental Neuropsychiatry, Department of Psychiatry, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstr. 5, 79104 Freiburg, Germany. 2Department for Psychiatry and Psychotherapy, Saarland University Medical Center, Kirrberger Str. 100, 66421 Homburg, Saar, Germany. 3Department of Radiology, Medical Physics, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Str. 60a, 79106 Freiburg, Germany. 4Department of Neurology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, 79106 Freiburg, Germany. 5Department for Child and Adolescent Psychiatry and Psychotherapy, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstr. 8, 79104 Freiburg, Germany. 6School of Medicine and Health Sciences and Psychotherapy – University Hospital, Karl-Jaspers-Klinik, Medical Campus University of Oldenburg, Hermann-Ehlers-Str. 7, 26160 Bad Zwischenahn, Germany. 7Clinic for Psychiatry Luzern, Schaffmattstrasse 1, 4915 St. Urban, Switzerland.

Received: 2 May 2016 Accepted: 14 February 2017
Published online: 07 March 2017

References
1. La M, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383:896–910.
2. Tebartz van Elst L, Maier S, Fangteich M, Tiedel R, Riedel A. High-functioning autism spectrum disorder as a basic disorder in adult psychiatry and psychotherapy: psychopathological presentation, clinical relevance and therapeutic concepts. Eur Arch Psychiatry Clin Neurosci. 2013;263 Suppl 2: S189–96.
3. Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem Res. 2012;37:681–9.
4. Tebartz van Elst L. Das Asperger-Syndrom im Erwachsenenalter: und andere hochfunktionale Autismus-Spektrum-Störungen. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft; 2013.
5. Brugha TS, McManus S, Barkant J, Scott F, Purdon S, Smith J, Bebbington P, Jenkins R, Meltzer H. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry. 2011;68:449–55.
6. Kim YS, Leventhal BL, Koh Y, Fombonne E, Laska E, Lim E, Cheon K, Kim S, Kim Y, Lee H, Song D, Grinker RR. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry. 2011;168:904–12.
7. Hofvander B, Delorme R, Chaste P, Nydén A, Wenzt E, Stålberg O, Herbrecht E, Stopan A, Ankarcéster H, Gillberg C, Råström M, Leboyer M. Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders. BMC Psychiatry. 2009;9:35.
8. Riedel A, Schrötzer C, Ebert D, Fangteich M, Bühl E, Tebartz van Elst L. Well educated unemployed—on education, employment and comorbidities in adults with high-functioning autism spectrum disorders in Germany. Psychiatr Pract. 2016;43(1):38–44.
9. Tebartz van Elst L, Maier S, Fangteich M, Endres D, Mueller GT, Nickel K, Ebert D, Lange T, Hennig J, Biscaldi M, Riedel A, Perlóv E. Disturbed cingulate glutamate metabolism in adults with high-functioning autism spectrum disorder: evidence in support of the excitatory/inhibitory imbalance hypothesis. Mol Psychiatry. 2014;19:314–25.
10. van Elst LT, Maier S, Fangteich M, Endres D, Mueller GT, Nickel K, Ebert D, Lange T, Hennig J, Biscaldi M, Riedel A, Perlóv E. Magnetic resonance spectroscopy comparing adults with high functioning autism and above average IQ. Mol Psychiatry. 2014;19:1251–6.
11. Pericso AM, Napolioli V. Autism genetics. Behav Brain Res. 2012;251:95–102.
12. Good P. A ‘unified field theory’ of autism. Autism Studies. 2016;21:21–21.
13. Deth R, Muratore C, Benzecry J, Power-Charnitsky V, Waly M. How environmental and genetic factors combine to cause autism: a redox/methylation hypothesis. Neurotoxicology. 2008;29:190–201.
14. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, Bonassi S. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med. 2012;52:2128–121.
15. Main P, Angley M, O’Doherty C, Thomas P, Fenech M. The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis. Nutr Metab (Lond). 2012;9:35.
16. Wood SJ, Yücel M, Pantelis C, Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore. 2009;38:396–5.
17. Rose S, Melnyk S, Pavlov O, Bai S, Nick T, Fyer R, James S. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry. 2012;2:134.
18. Berk M, Ng F, Dean O, Dodd S, Bush A. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29:346–51.
19. Schaefer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001;30:1191–212.
20. Maher P. The effects of stress and aging on glutathione metabolism. Ageing Res Rev. 2005;4:288–314.

21. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39(1):3–36.

22. Ross B, Blum S. Magnetic resonance spectroscopy of the human brain. Anat Rec. 2001;265:54–84.

23. Lagopoulos J, Herrmens D, Tobias-Webb J, Duffy S, Naisrith S, White D, Scott E, Hickie I. In vivo glutathione levels in young persons with bipolar disorder: a magnetic resonance spectroscopy study. J Psychiatr Res. 2013;47:412–7.

24. Durieux A, Horder J, Andreena Mendez M, Egerton A, Williams S, Wilson C, Span D, Murphy C, Robertson D, Barker G, Murphy D, McAlonan G. Cortical and subcortical glutathione levels in adults with autism spectrum disorder. Autism Res. 2015;9:429–35.

25. Chan K, Puts N, Snaussi K, Harris A, Barker P, Edden R. Echo time optimization for J-difference editing of glutathione at 3T. Magn Reson Med. 2016. [Epub ahead of print].

26. Emir U, Deelchand D, Henry P, Terpstra M. Noninvasive quantification of T2 and concentrations of ascorbate and glutathione in the human brain from the same double-edited spectra. NMR Biomed. 2011;24(3):263–9.

27. Wood SJ, Berger GE, Wellard RM, Proffitt T, McConchie M, Berk M, McCordy PD, Pantelis C. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis. 2009;33:54–7.

28. Terpstra M, Vaughan TJ, Uguril K, Lim KD, Schulz SC, Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA. 2005;18:276–82.

29. Matsuzawa D, Obara T, Saito K, Kanazawa Y, Yoshitome E, Nakazato Y, Koga M, Takanashi J, Tsuchiya F, Iyo H, Hashimoto K. N-acetylaspartate/glutamate ratio in Asperger syndrome compared with healthy controls. Poster presentation at the 17th Annual Meeting of the Japanese Society for Magnetic Resonance Imaging. 2011.

30. Bejjani A, O'Neill J, Kim J, Frew A, Yee V, Ly R, Kitchen C, Salamon N, Bernardi S, Anagnostou E, Shen J, Kolevzon A, Buxbaum J, Hollander E, Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Wood SJ, Berger GE, Wellard RM, Proffitt T, McConchie M, Berk M, McGorry PD, Emir U, Deelchand D, Henry P, Terpstra M. Noninvasive quantification of glutathione levels in healthy and clinically depressed subjects: evidence from an ascorbate/glutathione redox state study. PLoS ONE. 2012;7:e38786.

31. Vorst HCM, Bermond B. Validity and reliability of the Bermond-Vorst Asperghity Questionnaire. Pers Indiv Differ. 2001;30:413–21.

32. Baron-Cohen S, Wheelwright S, Robinson J, Woodbury-Smith M. The adult Asperger assessment (AAA): a diagnostic method. J Autism Dev Disord. 2005;35:807–19.

33. McAlonan G. Detection of elevated glutathione in meningiomas by quantitative in vivo 1H MRS. Magn Reson Med. 2003;49(4):632–7.

34. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659–68.

35. lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205–23.

36. Levine GL. The principles of quantification applied to in vivo proton MR spectroscopy. Eur J Radiol. 2006;67:218–25.

37. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–9.

38. Provencher SW. Automatic quantization of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14:460–4.

39. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;23:805–21.

40. Oner O, Devrimci-Ozguven H, Oktem F, Yagmurlu B, Baskak B, Munir K, Bejjani A, O'Neill J, Kim J, Frew A, Yee V, Ly R, Kitchen C, Salamon N, Bernardi S, Anagnostou E, Shen J, Kolevzon A, Buxbaum J, Hollander E, Wood SJ, Berger GE, Wellard RM, Proffitt T, McConchie M, Berk M, McGorry PD, Emir U, Deelchand D, Henry P, Terpstra M. Non-invasive quantification of glutathione levels in healthy and clinically depressed subjects: evidence from an ascorbate/glutathione redox state study. PLoS ONE. 2012;7:e38786.
67. Kreis R, Hofmann L, Kuhlmann B, Boesch C, Bossi E, Hüppi PS. Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med. 2002;48(6):949–58.

68. Satoh T, Yoshioka Y. Contribution of reduced and oxidized glutathione to signals detected by magnetic resonance spectroscopy as indicators of local brain redox state. Neurosci Res. 2006;55:34–9.

69. Endres D, Perlov E, Stich O, Rauer S, Waldkircher Z, Lange T, Mader I, Meyer P, Tebartz van Elst L. In vivo hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis. BMC Psychiatry. 2015;15:186.

70. Koga M, Serritella A, Messmer M, Hayashi-Takagi A, Hester L, Snyder S, Sawa A, Sedlak T. Glutathione is a physiologic reservoir of neuronal glutamate. Biochem Biophys Res Commun. 2011;409:596–602.

71. Novotny EJ, Fullbright RK, Pearl PL, Gibson KM, Rothman DL. Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol. 2003;54 Suppl 6:S25–31.

72. Baruth J, Wall C, Patterson M, Port J. Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review. Autism Res. 2013;6:119–33.

73. Friedman S, Shaw D, Artru A, Richards T, Gardner J, Dawson G, Posse S, Dager S. Regional brain chemical alterations in young children with autism spectrum disorder. Neurology. 2003;60:100–7.

74. Currais A, Maher P. Functional consequences of age-dependent changes in glutathione status in the brain. Antioxid Redox Signal. 2013;19:813–22.

75. Do K, Trabesinger A, Kirsten-Krüger M, Lauer C, Dydak U, Hell D, Heldboer F, Boesiger P, Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721–8.